Psychopharmacologia

, Volume 29, Issue 3, pp 221–230 | Cite as

The importance of dosage in antipsychotic drug administration — A review of dose-response studies

  • George Gardos
  • Jonathan O. Cole
  • Maressa Hecht Orzack
Human Pharmacology

Abstract

Methodologically adequate clinical dose-response studies with antipsychotic compounds are reviewed. A number of consistent findings have emerged. Treatment resistant schizophrenics, and schizophrenics under 40, hospitalized less than 10 years often benefit from high or very high doses of antipsychotics. Low dose treatment is to be considered for apathetic or depressed schizophrenics who are not floridly psychotic. Placebo or no medication is optimal for a hitherto not well defined subgroup. The usual clinical dose range appears to be most therapeutic for the remaining schizophrenic populations, probably including most out-patients. Methodological problems encountered in dose-response studies and clinical problems in posology are discussed.

Key words

Dose-Response Studies Posology Antipsychotic Dosage Treatment Resistant Schizophrenics Dose Scheduling Dose Equivalents 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brotman, R. K., Muzekari, L. H., Shanken, Phyllis, M.: Butaperazine in chronic schizophrenic patients: A double-blind study. Curr. ther. Res. 11, 5–8 (1969).Google Scholar
  2. Carscallen, H. B., Rockman, H., Lovegrove, T. D.: High dosage trifluoperazine in schizophrenia. Canad. Psychiat. Ass. J. 13, 459–461 (1968).Google Scholar
  3. Clark, M. L., Ramsey, H. R., Ragland, R. E., Rahhal, D. K., Serafetinides, E. A., Costiloe, J. P.: Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships. Psychopharmacologia (Berl.) 18, 260–270 (1970).Google Scholar
  4. Cole, J. O., Davis, J. M.: Clinical efficacy of the phenothiazines as antipsychotic drugs. In: Psychopharmacology: A review of progress, pp. 1057–1063. Ed. by D. H. Efron. Washington: U.S. Gov. Printing Office 1968.Google Scholar
  5. Curry, S. H., Davis, J. M., Jankowsky, D. S., Marshall, J. H. L.: Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch. gen. Psychiat. 22, 209–214 (1970).Google Scholar
  6. DeBuck, R. P.: The relative safety and efficacy of high and low dose administration of fluphenazine HCl to psychotic patients. Presented at C.I.N.P. Congress, Copenhagen 1972.Google Scholar
  7. Everett, G. M.: Pharmacological aspects of clinical psychotropic drug studies: A critique on the dose-response problem. In: Psychopharmacology. A review of progress, pp. 985–988. Ed. by D. H. Efron. Washington: U.S. Gov. Printing Office 1968.Google Scholar
  8. Ezhkov, A. A.: The treatment of schizophrenic patients with Triperidol (Trisedil). Zh. Nervopat. Psikhiat. 68, 1394–1400 (1968) (Rus.).Google Scholar
  9. Galbrecht, C. R., Klett, C. J.: Predicting response to phenothiazines: The right drug for the right patient. J. nerv. ment. Dis. 147, 173–183 (1968).Google Scholar
  10. Gardos, G., Cole, J. O.: The dual action of Thiothixene. Arch. gen. Psychiat. (in press).Google Scholar
  11. Gittleman-Klein, R., Klein, D. F.: Long-term effects of „Antipsychotic” agents: A review. In: Psychopharmacology. A review of progress, pp. 1119–1153. Ed. by D. H. Efron: Washington: U.S. Gov. Printing Office 1968.Google Scholar
  12. Goldberg, S. C.: Prediction of response to antipsychotic drugs. In: Psychopharmacology. A Review of Progress, pp. 1101–1117. Ed. by D. H. Efron. U.S. Gov. Printing Office 1968.Google Scholar
  13. Hollister, L. E., Overall, J. E., Bennett, J. L., Kimball, I., Shelton, J.: Specific therapeutic actions of acetophenazine, perphenazine and benzquinamide in newly admitted schizophrenic patients. Clin. Pharmacol. Ther. 8, 249–255 (1967).Google Scholar
  14. Itil, T. M., Keskiner, A., Heinemann, L., Han, T., Gannon, P., Hsu, W.: Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride. Psychosomatics 11, 456–463 (1970).Google Scholar
  15. Itil, T. M., Saletu, B., Hsu, W., Kiremitci, N., Keskiner, A.: Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. Acta psychiat. scand. 47, 440–451 (1971).Google Scholar
  16. Klein, D. F., Davis, J. M.: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: The Williams & Wilkins Co. 1969.Google Scholar
  17. Overall, J. E., Hollister, L. E., Honigfeld, G., Kimbell, I. H., Meyer, F., Bennett, J. L., Caffey, E.: Comparison of acetophenazine with perphenazine in schizophrenics: Demonstration of differential effects based on computer-derived diagnostic models. Clin. Pharmacol. Ther. 4, 200–208 (1963).Google Scholar
  18. Platz, A. R., Klett, C. J., Caffey, E. M., Jr.: Selective drug action related to chronic schizophrenic subtype. Dis. nerv. Syst. 28, 601–605 (1967).Google Scholar
  19. Polvan, N., Yagcioglu, V., Itil, T. M., Fink, M.: High and very high dose fluphenazine in the treatment of chronic psychosis. In: Proceedings of the VI International Congress of the C.I.N.P. Tarragona, Excerpta Medica International Congress Series, No. 180, pp. 495–497 (1968).Google Scholar
  20. Prien, R. F., Cole, J. O.: High dose chlorpromazine therapy in chronic schizophrenia. Arch. gen. Psychiat. 18, 482–495 (1968).Google Scholar
  21. Prien, R. F., Levine, J., Cole, J. O.: High dose trifluoperazine therapy in chronic schizophrenia. Amer. J. Psychiat. 126, 53–61 (1969).Google Scholar
  22. Rosati, D.: Prolonged high dosage ataractic medication in chronic schizophrenia. Brit. J. Psychiat. 110, 61–63 (1964).Google Scholar
  23. Schiele, B., Mendelson, R. M., Penman, A. S., Schofield, W.: Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiat. Quart. 33, 252–259 (1959).Google Scholar
  24. Simpson, G. M., Amin, M., Kurz-Bartholini, E., Watts, P. T. S., Laska, E.: Problems in the evaluation of the optimal dose of a phenothiazine (butaperazine). Dis. nerv. Syst. 29, 478–484 (1968).Google Scholar
  25. Voskresenskaya, A. N., Leyzerovich, F. A.: Opyt primeneniya malykh doz stelazina pri lechenii psykhicheskikh zabolevaniy (Use of small doses of Stelazine in the treatment of mental disease). In: Voprosy Psikhofarmakologii (Problems in Psychopharmacology). Moscow: Ministry of Public Health, Scientific Research Institute of Psychiatry, pp. 150–154 (1967).Google Scholar
  26. Wilkens, B., Malitz, S.: Some problems of dose variation in the use of tranquilizing drugs. Amer. J. Psychiat. 117, 23–29 (1960).Google Scholar
  27. Williams, J. R., Solecki, R. T., Puttkammer, S.: Effects of single, combined and non-drug treatments of chronic mental patients. Dis. nerv. Syst. 30, 696–701 (1969).Google Scholar

Copyright information

© Springer-Verlag 1973

Authors and Affiliations

  • George Gardos
    • 1
  • Jonathan O. Cole
    • 1
  • Maressa Hecht Orzack
    • 2
  1. 1.Boston State HospitalBoston
  2. 2.Boston University School of MedicineBoston

Personalised recommendations